Pharmacy Utilization Analysis in Portugal


Learning outcomes of the curricular unit 

At the end the students will / should be able to:

Understand the interrelationships at different stages of the product cycle, to identify the role of different actors and understand the effect of policies on drug use;

Understand the role of various professionals in the use of medications, within a framework that ensures its effectiveness and patient safety, according to national and international guidelines;

Understand the financing system of medicines and management of the system of reference prices applied to the use of generic drugs;

Analyze the effective use of medicines in Portugal and outpatient hospital care;

Understand the tools of analysis for economic evaluation of medicines.




General characterization





Responsible teacher

Ana Maria Escoval


Weekly - Available soon

Total - 26

Teaching language



Requirements for frequency 

No requeriments.



APIFARMA - Política de acesso ao medicamento em Portugal. Lisboa: Apifarma, Janeiro 2013.

DELOITTE. APIFARMA – Relatório: Caracterização das falhas de abastecimento no mercado farmacêutico nacional: atualização 2013. Lisboa: Deloitte, 2013.

INFARMED - Relatório “Monitorização do Mercado de Medicamentos em Ambulatório”. Lisboa: Infarmed, Janeiro 2014.

OECD - Health at a glance 2012: OECD indicators. [Em linha]. Paris: OECD Publishing. Organization for Economic Co-Operation and Development, 2013. [Consult. 17.03.2014]. Disponível em

THINK TANK INOVAR SAÚDE - Pensar a saúde: promover e disponibilizar a inovação aos cidadãos. Lisboa: Escola Nacional de Saúde Pública, Dezembro 2013.

Teaching method

Teaching methodologies (including evaluation)

Theoretical sessions;

Seminars (critical analysis and discussion of case studies);

Group work presentation and discussion.


Punctuality and attendance (5%)

Participation (10%)

Individual test with 10 multiple choice questions (35%)

Group work (50%)

Evaluation method


Punctuality and attendance (5%)

Participation (10%)

Individual test with 10 multiple choice questions (35%)

Group work (50%)

Subject matter


Sessions 1 and 2

  • Introduction to Curriculum Module
  • The cycle of medicament

 Sessions 3 and 4

  • Health Technologies evaluation  

 Sessions 5 and 6

§  Analysis of Access to Therapeutic Innovation

 Sessions 7 and 8

  • Drug policies analysis and health system organization

 Sessions 9 and 10

  • Pharmacovigilance and drug safety

  Sessions 11 and 12

  •  Evaluation

 Sessions 13 and 14

  • Seminar